IGM Biosciences Inc. has announced that it has received a notice from The Nasdaq Stock Market LLC indicating non-compliance with the minimum Market Value of Listed Securities (MVLS) of 50 million, a requirement for continued listing on The Nasdaq Global Select Market. As per the Nasdaq Listing Rule 5450(b)(A)$, the company must regain compliance by December 3, 2025, which entails maintaining an MVLS of at least $50 million for 10 consecutive business days. Currently, IGM Biosciences' common stock continues to trade under the symbol "IGMS." The company is exploring options to address this issue, which may include transferring its listing to The Nasdaq Capital Market. If compliance is not restored by the deadline, the company faces potential delisting.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.